Free Newsletter

About | View Sample | Privacy
Related Topics >> smallpox | Bavarian Nordic

Bavarian Nordic soars on FDA vax OK


Shares of Bavarian Nordic jumped more than 20 percent this morning after the company reported that the FDA had raised a green flag for the production and delivery of its smallpox vaccine Imvamune. Analysts cheered the move as a major event for the biopharma company. "This represents a transformational step in the company lifecycle of Bavarian Nordic from being a developmental, R&D focused company to an order producing pharmaceutical business," S&P says in a note. Bavarian release | Report

Email Twitter Facebook LinkedIn StumbleUpon
Get Your FREE FierceVaccines Email Newsletter:
Be the first to comment
More stories about smallpox   Bavarian Nordic  


Post new comment

The content of this field is kept private and will not be shown publicly.

More information about formatting options

To combat spam, please enter the code in the image.